When a novel coronavirus struck in early 2020, Pfizer’sPFE1.22%increase; green up pointing triangle chief executive, Dr. Albert Bourla, saw an opportunity to help save the world. He pushed the ...

Pfizer's CEO said President Donald Trump's tariffs and uncertainty are holding the company back from making "tremendous investments" in the US. In a first-quarter earnings call on Tuesday, chief ...

As Pfizer navigates these challenges, it faces rising competition from agile biotech firms wielding AI, gene editing, and mRNA technologies. By 2030, these innovators could surpass Pfizer’s drug ...

Pfizer stock fell about 8% when the market opened on Dec. 13 in a knee-jerk reaction to forward-looking estimates that didn't align with Wall Street's predictions.

During an earnings call that same month, Pfizer executives said they expected roughly 24% of the U.S. population to get an annual Covid booster in 2023. But by December, only around 17% of U.S ...

Pfizer Inc. PFE will release earnings results for the first quarter, before the opening bell on Tuesday, April 29.. Analysts expect the New York-based company to report quarterly earnings at 68 ...

Pfizer had announced several days earlier it was embarking on a $3.5 billion cost-cutting effort, including layoffs. Bourla and the other executives explained the company was positioning for growth.

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. CNN values your feedback 1.

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value and an activist investor is agitating for change.

Pfizer will spend $43 billion to buy Seagen and deepen its reach into treating cancer. The pharmaceutical giant said Monday that it will pay $229 in cash for each Seagen share.

Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the drug after liver issues affected one patient. Fox Business.

Pfizer is recalling multiple blood pressure medications due to elevated levels of nitrosamine, which can increase the risk of cancer.. The company said it is voluntarily recalling six lots of ...